Hamdan Al-Jahdali
Overview
Explore the profile of Hamdan Al-Jahdali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al-Jahdali H, Al-Lehebi R, Lababidi H, Alhejaili F, Habis Y, Alsowayan W, et al.
Ann Thorac Med
. 2025 Feb;
20(1):1-35.
PMID: 39926399
The Saudi Thoracic Society (STS) developed an updated evidence-based guideline for diagnosing and managing chronic obstructive pulmonary disease (COPD) in Saudi Arabia. This guideline aims to provide a comprehensive and...
2.
Alsehali A, Alrajih H, Al-Jahdali H, Al-Safi E, Layqah L, Baharoon S
J Epidemiol Glob Health
. 2024 Oct;
14(4):1591-1601.
PMID: 39470976
Introduction: Tuberculosis (TB) is a significant contributor to morbidity and mortality. With a progressively aging population, TB is increasingly encountered in older adults. Understanding the clinical presentation and optimal treatment...
3.
Neffen H, Yorgancioglu A, Al-Jahdali H, McLachlan S, Myers J, Bly C, et al.
Asian Pac J Allergy Immunol
. 2024 Jun;
42(3):207-221.
PMID: 38877849
Background: Several studies suggest that patients often under-estimate their asthma symptoms and over-estimate their level of asthma control, potentially putting them at risk of undertreatment with inhaled corticosteroids. Objective: To...
4.
Emad Y, Ragab Y, Farber H, Erkan D, Ibrahim O, Kindermann M, et al.
Thromb Res
. 2024 May;
239:109040.
PMID: 38795561
Background And Aim: Hughes-Stovin syndrome (HSS) is a rare systemic vasculitis with widespread venous/arterial thrombosis and pulmonary vasculitis. Distinguishing between pulmonary embolism (PE) and in-situ thrombosis in the early stages...
5.
Abuabat F, Badri M, Abuabat S, Alsultan S, Baharoon S, Alharbi A, et al.
Int J Mycobacteriol
. 2023 Dec;
12(4):407-411.
PMID: 38149535
Background: Tuberculosis (TB) is the primary infectious cause of mortality worldwide. Although TB incidence and prevalence are declining, the use of immunosuppressive drugs and the growing prevalence of immunocompromising conditions...
6.
Ayaz Khan M, Sherbini N, Alyami S, Al-Harbi A, Alrajhi S, Abdullah R, et al.
Avicenna J Med
. 2023 Dec;
13(4):230-236.
PMID: 38144909
Decisions on the management of interstitial lung diseases (ILD) and prognostication require an accurate diagnosis. It has been proposed that multidisciplinary team (MDT) meetings for ILD (ILD-MDT) improve these decisions...
7.
Al-Jahdali H, Ahmed A, Al-Harbi A, Khan A, ALGamedi M, Alyami S, et al.
Ann Thorac Med
. 2023 Sep;
18(3):124-131.
PMID: 37663882
Background: Although chronic respiratory diseases are prevalent in Saudi Arabia, there are limited data on the patient burden and associated factors. The aim of this study is to identify the...
8.
Khan M, Ghamdi B, Alhamadi M, Rajendram R, Alyami S, Al-Gamedi M, et al.
Ann Thorac Med
. 2023 Jun;
18(2):79-85.
PMID: 37323372
Background: The prognosis of idiopathic pulmonary fibrosis (IPF) can be predicted by the gender, age, and physiology (GAP) index. However, antifibrotic therapy (i.e., nintedanib and pirfenidone) may improve survival. Aims:...
9.
Khan M, Al-Jahdali H
Neurosciences (Riyadh)
. 2023 Apr;
28(2):91-99.
PMID: 37045455
Although not fully understood, sleep is accepted as a vital and organized sequence of events that follows a regular cyclic program each night to ensure the human body can perform...
10.
Khan M, Sherbini N, Alyami S, Al-Harbi A, Al-Ghamdi M, Alrajhi S, et al.
Ann Thorac Med
. 2023 Mar;
18(1):45-51.
PMID: 36968327
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive age-related lung disease causing relentless fibrosis of the lung parenchyma. Currently, pirfenidone and nintedanib are the two antifibrotic drugs, approved for...